BIVI vs. APM, ADXN, TCRT, RNXT, GLTO, VINC, FLGC, NRSN, ONTX, and KALA
Should you be buying BioVie stock or one of its competitors? The main competitors of BioVie include Aptorum Group (APM), Addex Therapeutics (ADXN), Alaunos Therapeutics (TCRT), RenovoRx (RNXT), Galecto (GLTO), Vincerx Pharma (VINC), Flora Growth (FLGC), NeuroSense Therapeutics (NRSN), Onconova Therapeutics (ONTX), and KALA BIO (KALA). These companies are all part of the "pharmaceutical preparations" industry.
Aptorum Group (NASDAQ:APM) and BioVie (NASDAQ:BIVI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability, earnings and community ranking.
3.8% of Aptorum Group shares are held by institutional investors. Comparatively, 4.6% of BioVie shares are held by institutional investors. 64.0% of Aptorum Group shares are held by company insiders. Comparatively, 4.8% of BioVie shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Aptorum Group has a beta of 0.7, suggesting that its stock price is 30% less volatile than the S&P 500. Comparatively, BioVie has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500.
In the previous week, BioVie had 5 more articles in the media than Aptorum Group. MarketBeat recorded 7 mentions for BioVie and 2 mentions for Aptorum Group. BioVie's average media sentiment score of 0.81 beat Aptorum Group's score of 0.74 indicating that Aptorum Group is being referred to more favorably in the media.
BioVie has a consensus target price of $8.00, indicating a potential upside of 1,525.03%. Given Aptorum Group's higher probable upside, analysts plainly believe BioVie is more favorable than Aptorum Group.
Aptorum Group has higher revenue and earnings than BioVie.
BioVie's return on equity of 0.00% beat Aptorum Group's return on equity.
Aptorum Group received 25 more outperform votes than BioVie when rated by MarketBeat users. Likewise, 68.33% of users gave Aptorum Group an outperform vote while only 64.00% of users gave BioVie an outperform vote.
Summary
Aptorum Group beats BioVie on 8 of the 13 factors compared between the two stocks.
Get BioVie News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIVI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BIVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
